# Vivo Capital and ZQ Capital to acquire Angiotech Pharmaceuticals

Angiotech Pharmaceuticals entered into a definitive agreement to be acquired by an investor group led by Vivo Capital and ZQ Capital, including GSO Capital Partners and others. Terms were not disclosed.

- Type: Acquisition
- Announced: 2016-12-19
- Where: Vancouver, British Columbia, Canada
- Status: announced
- Products: needles, sutures, surgical knives
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Vivo Capital](https://endata.com/companies/20844.md) (acquirer)
- [ZQ Capital](https://endata.com/companies/20845.md) (acquirer)
- [Angiotech Pharmaceuticals](https://endata.com/companies/20846.md) (target)
- [GSO Capital Partners](https://endata.com/companies/20847.md) (investor)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/vivo-capital-and-zq-capital-limited-enter-into-an-agreement-to-acquire-angiotech-pharmaceuticals-300380542.html), 2016-12-19: "Angiotech Pharmaceuticals (Canada) today announced that it has entered into a definitive agreement to be acquired by a group of investors led by Vivo Capital LLC and ZQ Capital Limited."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.